Heartflow, known for its AI-based CCTA evaluations, appears to be going public. The news follows years of momentum for the California-based company, including improved Medicare reimbursements for cardiac CT and a new Category I CPT code for its Plaque Analysis software.
One of the study's most significant findings was that patients managed using the advanced AI software saw LDL cholesterol drops of 18.7 mg/dL, with a 15% reduction in their risk of a cardiac event. Even patients with no calcified plaque saw significant changes in care management.
A heart team chose to perform BASILICA before valve-in-valve TAVR in a failed Lotus device to help minimize the risk of complications. These scenarios will likely grow more and more common as patients outlive their TAVR valves.